Treats nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus…. ANDA 202801, held by Hetero Labs Ltd V. Levofloxacin.
As of Nov 16, 2026, ANDA 202801 (Levofloxacin), held by Hetero Labs Ltd V, was first approved by FDA on Jan 8, 2015, with 6 approved supplements and 0 published complete response letters.
Levofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated (1, 12.4).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 8, 2015 | Original application | Approved |
| Levofloxacin250MG · tablet;oral | Levofloxacin | Rx |
| Levofloxacin500MG · tablet;oral | Levofloxacin | Rx |
| Levofloxacin750MG · tablet;oral | Levofloxacin | Rx |
| Sep 20, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Sep 27, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| May 3, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 24, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 24, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 24, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 8, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters